Strictly beating the crime of dangers of drugs; Baiyunshan terminates the spin -off and listed;

The seventh batch of the national collection documents this week was officially released, and it was clearly opened in Shanghai on July 12. The pharmaceutical industry must be tested again.

According to the National Medical Insurance Administration: As of the end of May this year, 57,100 medical institutions have been directly settled in the country ’s direct settlement of hospitalization expenses. In the first five months of this year, the direct settlement costs of hospitalization expenses across the country reached 450.17 billion yuan, and the fund paid 261.31 261.31 100 million yuan, the fund payment ratio was 58.1%.

This week, the State Council established a leading group of criminal criminals that harms drug safety violations. The team will urge the implementation of the implementation of the relevant laws and regulations and major policies and measures of drug safety; supervise the handling of major cases of crimes that endanger drug safety illegal crimes.

In terms of the company, Bai Yunshan suspended the IPO of Guangzhou Pharmaceuticals, and the framework of Asley -Chan's organization was adjusted. Sanofi, Ogaron, Baiji Shenzhou, Xi'an Yangsen and other companies changed personnel changes. Indications are approved in China.

The Jianzhi Bureau organizes more hot information as follows:

Heavy policy

1. Specialty nurse will have prescription rights

On the afternoon of June 23, the tenth meeting of the Standing Committee of the 7th People's Congress of Shenzhen approved the revised draft of the "Shenzhen Special Economic Zone Medical Regulations". Among them, Article 64 stipulates that the nurse is encouraged to participate in the professional training of specialist nurses according to the needs of the discipline to obtain a specialized nursing certificate. The following practice activities can be carried out in the nursing specialist clinic or community health service agency: the application form, the treatment application form, and the external category of the treatment drug.

In recent years, "specialized nurses" have begun to rise in China. They have an independent expertise in one aspect, and they can go out of the clinic independently like a doctor. However, they did not have "prescription rights". When they were out of the clinic, they had to ask a doctor to open a prescription for patients. The newly revised "Medical Regulations" in Shenzhen draw on the practices of developed countries in Europe and the United States, and given a certain prescription right to nurses in the country, and can issue "prescriptions" for inspections, treatment, and external drugs.

2. Over 57,100 medical insurance settlement hospitals for cross -provinces and other places

According to the National Medical Insurance Bureau, as of the end of May 2022, 57,100 medical institutions have been directly settled in the nation ’s hospitalization expenses across provinces; from January to May, the national hospitalization expenses were directly settled by 1.9902 million across provinces, involving medical expenses 450.17 billion yuan The fund payment is 26.131 billion yuan, and the fund payment ratio is 58.1%.

As of the end of May 2022, the national outpatient expenses were directly settled by 62,700 direct -network designated medical institutions and 146,600 fixed -point retail pharmacies; from January to May, the national outpatient costs were directly settled by 8.6759 million people, involving a medical expenses of 2.12 billion. Yuan, the fund payment of 1.267 billion yuan, the fund payment ratio is 59.8%.

3. The state set up a working group to combat harmful drug safety crimes

On June 24, the State Council issued a notice saying that the leading group of criminal criminal criminals in harmful drug safety is established.

According to the contents of the notice, the group should fully implement the relevant decision -making and deployment of the Party Central Committee and the State Council, coordinate and coordinate and combat the work of hazarding drug safety illegal crimes, and urge the implementation of the relevant laws and regulations and major policies and measures of drug safety; Disposal of major cases of illegal crimes.

4.383 equipment products enter the innovative green channel

On June 15th, the State Drug Administration issued a rapid view of the pharmaceutical regulatory policy, which took stock of the policies and results of encouraging medical device innovation in recent years.

According to the State Drug Administration, in order to encourage medical device innovation and encourage the high -quality development of the industry, the State Drug Administration was amended and released the "Special Examination Procedures for Innovation Medical Device" in 2018; "It also proposed to give priority review and approval of innovative medical devices. At present, more than 383 products have entered the green channel of innovative medical equipment, and 155 products with strong innovation, high technical content, and significant clinical value are listed.

5. The seventh batch of National Cai will open the bid on July 12

On June 20, Shanghai Sunshine Pharmaceutical Procurement Network notified that the seventh batch of national collection was opened on July 12, and the location was Dongfangmei Valley Forum Hotel No. 399, Lakeside Road, Fengxian District, Shanghai.

According to the procurement variety catalog, this collection involves 61 varieties and 125 specifications including Omeprazole injection, iodine glycol injections, and U.S. -chichel Hydrochloride Slow -release capsules. This time, the national mining rules have been added to the alternatives: according to the original rules, the selection area is first;

Industry affairs

1. Baiyunshan temporarily terminate Guangzhou pharmaceutical spin -off IPO

On the evening of June 23, Bai Yunshan issued an announcement saying that it was decided to temporarily suspend the promotion of Guangzhou Pharmaceutical Spinning Listing Plan. The relevant person in the Baiyunshan Directors told the media that followed by the market environment and other reality, it may be considered to be restarted. But for the specific time to start, the person said, "not predicting."

In August 2021, Li Chuyuan, Secretary of the Party Committee and Chairman of Guangyao Group, publicly stated that the capital plan during the "Fourteenth Five -Year Plan" period was to establish more than 5 listed companies. Today, in 2025, there are only three and a half years left.

2. Astrakan's organizational framework adjustment

Astraikon China has made organizational adjustments and established a new CCIC innovation management team, which will be officially implemented from July 1.

The Jianzhi Bureau was informed that the innovative market positions of Astraika's business units will be officially transferred to the CCIC Innovation Disease Management Team of Digital and Commercial Innovation. China Vice President, Ms. Zhu Lizhen, head of the Digital and Commercial Innovation Department, Business Strategy and Excellent Operation Department. "Channel" and "Digitalization" are the two keywords for the adjustment of the organizational structure of Astraon in China since this year. The company's management hopes to use a digital way to leverage the full -chain capabilities from R & D to marketing and open up the grass -roots market in a new way.

3. Sanofi China changes coach

On June 22, Sanofi China officially announced that after the company's former president of Greater China, He Enting, the company, has served as the global head of Sanofi Digital Division since August 1. He will work at the headquarters of Sanofi Paris. After He Enting's resignation, the post of President of Sanofi Greater China was replaced by Shiwang.

Shi Wang had previously worked in the head of Ogaron China and led the Merck-Ogaron split project. He also worked in Yangsen, Astrikan and Merck in Xi'an. The Jianzhi Bureau was informed that the person in charge of Ogaron China still had a vacancy.

In addition, many foreign companies have changed this week. Xi'an Yangsen announced that Wang Jianxin, the head of the Porte Department of the Department of Immune and Pulmonary High pressure, will leave the company on July 10, 2022 to seek external development opportunities. Liu Yan, vice president of Baiji Shenzhou and head of marketing in Greater China, announced his departure. Chen Yongzheng also resigned from the position of independent and non -executive directors of Baiji Shenzhou.

New drug inventory

1. Yanye Yixin Guan Oral medication was suspended for approval

On June 22, the S-217622 emergency authorization application submitted by Shionogi based on phase II data was suspended by the Japanese PMDA, saying "more careful discussions." S-217622 is a oral 3CL protease inhibitor jointly developed by the University of Hokkaido and Yanye Yiyi. Its mechanism is the same as Paxlovid, a COVID-19 drug approved by Pfizer.

2. Alzheimer's Diseases is rejected by FDA

The American FDA Psychiatric Pharmaceuticals Consulting Committee voted at 9: 3 to oppose ACADIA NuPlazid tablets for the treatment of new drug applications (SDNA) related to Altzheimer's psychiatric illness and delusion. It is believed that the existing evidence does not support this drug to have a clear effect on the relevant people.

3. The fourth indication of Siten Mipida is approved

Merck announced the approval of Siciestab's formal obtained by the State Drug Administration and combined with radiotherapy for the treatment of patients with LA SCCHN (LA SCCHN) in the treatment of local advanced periods. This is the fourth adaptation approved by the drug in China.

- END -